Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Hutchmed Share Price
  4. Hutchmed Share Regulatory News
  5. Form-20F Publication

Pin to quick picksHutchmed Regulatory News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
154.00    1.50 (0.96%)
Bid:
154.00
Ask:
162.50
Spread: 8.50 (5.519%)
Market Cap: £1.32b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Form-20F Publication

3 Mar 2020 14:18

RNS Number : 8821E
Hutchison China Meditech Limited
03 March 2020
 

 

 

Press release

 

Publication of Form 20-F

 

 

London: Tuesday, March 3, 2020: Hutchison China MediTech Limited ("Chi-Med") (NasdaqAIM: HCM) today published the Form 20-F for the financial year ended December 31, 2019. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/8821E_1-2020-3-3.pdf and also on the website of the Company at www.chi-med.com.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

CONTACTS

Investor Enquiries

 

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

David Dible, Citigate Dewe Rogerson

+44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com

Xuan Yang, Solebury Trout

+1 (415) 971 9412 (Mobile)xyang@troutgroup.com

 

 

Media Enquiries

 

UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)anthony.carlisle@cdrconsultancy.co.uk

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)bmiles@troutgroup.com

Asia

- Joseph Chi Lo, Brunswick

+852 9850 5033 (Mobile)jlo@brunswickgroup.com

 

- Zhou Yi, Brunswick

+852 9783 6894 (Mobile)yzhou@brunswickgroup.com

 

 

Nominated Advisor

 

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAJJMITMTMMBIM
12345678910
Date   Source Headline
30th Jun 20259:30 amRNSChina Approval based on Phase III SACHI Trial
30th Jun 20259:30 amRNSTotal Voting Rights
30th Jun 20259:30 amRNSBlocklisting Six Monthly Return
10th Jun 202511:00 amRNSGrant of Share Options and Awards under LTIP
5th Jun 20257:00 amRNS-RHUTCHMED and Innovent Announce NDA Acceptance
2nd Jun 20257:00 amRNS-RHUTCHMED Highlights SACHI Phase III Data at ASCO
30th May 20259:30 amRNSTotal Voting Rights
23rd May 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
13th May 202511:45 amRNSAGM held on May 13, 2025 – Poll Results
24th Apr 20257:00 amRNS-RHUTCHMED - Data to be Presented at AACR 2025
22nd Apr 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase II Study
7th Apr 20259:30 amRNS2024 Annual Report and Notice of AGM
31st Mar 202510:30 amRNSExtraordinary General Meeting – Poll Results
21st Mar 202510:00 amRNS-RNMPA Conditional Approval for TAZVERIK®
20th Mar 20259:30 amRNSRetirement of Independent Non-executive Directors
20th Mar 20257:00 amRNS-RHUTCHMED Highlights Savolitinib SAVANNAH Phase II
19th Mar 20251:45 pmRNS-RPublication of Form 20-F
19th Mar 202511:00 amRNS2024 Final Results and Business Updates
19th Mar 20257:00 amRNS-RPhase II/III Study of Fruquintinib and Sintilimab
14th Mar 20259:30 amRNSAdoption of the 2025 Long Term Incentive Plan
14th Mar 20259:30 amRNSVesting of awards under Long Term Incentive Plan
13th Mar 20259:30 amRNSNotice of Extraordinary General Meeting
6th Mar 202510:00 amRNS-RCompleted Enrollment of Phase II Study
5th Mar 202510:00 amRNSDirectorate Change
3rd Mar 20257:00 amRNSOverseas Regulatory Announcement
28th Feb 20253:00 pmRNSOverseas Regulatory Announcement
19th Feb 20258:30 amRNSNotice of Results
28th Jan 20259:00 amRNSOverseas Regulatory Announcement
14th Jan 20257:00 amRNS-RFull Approval for ORPATHYS in China
2nd Jan 20257:00 amRNSOverseas Regulatory Announcement
2nd Jan 20257:00 amRNSUS$608m Divestment of Non-Core Joint Venture
31st Dec 20248:30 amRNSAppointment of Joint Corporate Broker
30th Dec 20248:30 amRNSBlocklisting Six Monthly Return
29th Nov 20248:30 amRNSTotal Voting Rights
20th Nov 20249:30 amRNSAppointment of Independent Non-executive Director
31st Oct 20248:30 amRNSTotal Voting Rights
21st Oct 20249:30 amRNSVesting of awards under the LTIP
16th Oct 20247:00 amRNSSAVANNAH: clinically meaningful response rate
24th Sep 20248:00 amRNSJapan Approval for FRUZAQLA
30th Aug 20249:30 amRNSTotal Voting Rights
30th Aug 20247:00 amRNSUpdate on Fruquintinib for Gastric Cancer in China
22nd Aug 20249:30 amRNSStandard form for notification of major holdings
6th Aug 202410:00 amRNSLTIP and Share Option Scheme
31st Jul 202412:00 pmRNS2024 Interim Results and Business Updates
28th Jun 20249:30 amRNSTotal Voting Rights
28th Jun 20249:30 amRNSBlocklisting Six Monthly Return
26th Jun 20249:30 amRNSHUTCHMED to Announce 2024 HY Financial Results
24th Jun 20247:00 amRNSEuropean Commission Approval for FRUZAQLA
7th Jun 20247:00 amRNSHUTCHMED Initiates Phase I Trial of HMPL-506
3rd Jun 20247:00 amRNSNature Medicine Publish Phase III FRUTIGA Results
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
GKP
Gulf Keystone Petroleum
LSE
1.71%
PTEC
Playtech
LSE
-3.53%
SBRE
Sabre Insurance Group
LSE
-0.12%
GAW
Games Workshop
LSE
0.78%
Trending
NANO
Nanoco
LSE
17.24%
QHE
Quantum Helium
LSE
6.38%
GST
GSTechnologies
LSE
-4.82%
KEFI
Kefi Gold & Copper
LSE
-0.35%
HEX
Helix Exploration
LSE
-3.23%